Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 12/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23340702 | 0.96 | CHRM1 (0.37) | NUDT5PLK1HRH1KCNH2TSHR | |
| SCHEMBL23340703 | 0.90 | NUDT5 (0.38) | NUDT5PLK1TSHRMAPK1MAPT | |
| SCHEMBL23340638 | 0.90 | NUDT5 (0.36) | NUDT5PLK1TSHRMAPK1MAPT | |
| SCHEMBL23340556 | 0.89 | NUDT5 (0.47) | NUDT5PLK1TSHRMAPK1MAPT | |
| SCHEMBL23340555 | 0.89 | HPGD (0.44) | NUDT5TSHRMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL23340498 | 0.83 | NUDT5 (0.48) | NUDT5PLK1TSHRMAPK1MAPT | |
| SCHEMBL23340643 | 0.83 | NUDT5 (0.37) | NUDT5PLK1TSHRMAPK1MAPT | |
| SCHEMBL23340337 | 0.81 | PLK1 (0.39) | PLK1TSHRMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL23297653 | 0.81 | NUDT5 (0.57) | NUDT5TSHRMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL23340325 | 0.79 | NUDT5 (0.54) | NUDT5PLK1TSHRMAPK1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128566-A1 | NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128566-A1 | NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE | ADORA2A, HPRT1, PNP | NUDT5 105/4885PLK1 2110/4885CYP2D6 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.